Serving Overlooked PatientsSM
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indication and Additional Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications and Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indication and Additional Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications and Safety Information.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
News & Events
ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China
NEW YORK, NY, UNITED STATES, January 14, 2026 — ACA Pharma and Azurity Pharmaceuticals are pleased to announce that they have entered into an exclusive distribution partnership under which ACA Pharma will commercialize FerabrightTM (ferumoxytol injection) across Macau, Hong Kong, Singapore, the Guangdong–Hong Kong–Macao Greater Bay Area (GBA) and Mainland China.
Azurity Pharmaceuticals Announces the Availability of JAVADIN™ (clonidine hydrochloride) Oral Solution
Woburn, MA—December 18, 2025—Azurity Pharmaceuticals, Inc. announced today the availability of JavadinTM (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. Lowering blood pressure has been shown to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.